Plasma volume expansion via colloid osmotic effect

Plasma volume expansion via colloid osmotic effect is not a discrete molecular target but rather a physiological process exploited therapeutically by administering intravenous fluids containing large molecules ("colloids"), such as albumin, gelatin derivatives, dextrans, or synthetic starches. These macromolecules increase the oncotic pressure within blood vessels—drawing water from surrounding tissues into the circulation—and thus expand plasma/intravascular volume more effectively than crystalloids. This approach is used clinically to treat hypovolemia resulting from hemorrhage, shock states, dehydration, or critical illness. The efficacy and safety profile depend on both patient factors and properties of each product class; notable risks include coagulopathy with some synthetic starches and potential for renal injury or tissue edema when endothelial integrity is compromised. Because this entry describes a therapeutic principle/mechanism rather than a single protein/receptor/enzyme/transporter/etc., it should not be considered a canonical drug target but rather an important pharmacodynamic concept underlying several resuscitation therapies.[1][2][3][4][5]

Other names

Colloid osmotic effectPlasma volume expansion (colloid)Intravascular volume expansion (colloid)

The mechanism involves the administration of colloid solutions containing large molecules that remain in the intravascular space. These molecules exert an oncotic pressure ("colloid osmotic pressure") that draws water from the interstitial compartment into the blood vessels, thereby expanding plasma volume and maintaining blood pressure[2][4][5][6]. The effect is dependent on molecular size and structure; larger molecules tend to persist longer in circulation[2][3].